Tumor Response Assessment to Treatment with [177Lu-DOTA0,Tyr3]Octreotate in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Differential Response of Bone Versus Soft Tissue Lesions

#393

Introduction: Little is known about the treatment response of bone lesions to treatment with [177Lu-DOTA0,Tyr3]octreotate (177Lu-octreotate).

Aim(s): To compare the response of bone and soft tissue lesions to treatment with 177Lu-octreotate in patients with gastroenteropancreatic neuroendocrine tumors (GEPNETs).

Materials and methods: Forty-two patients who: 1) had bone metastases that were positive on [111Indium-DTPA0]octreotide scintigraphy (SRS) before treatment; 2) had soft tissue lesions; and 3) had had a minimum of one follow-up CT, were studied. Lesions were scored on CT and bone lesions also on SRS before and after treatment.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Van Vliet E, Hermans J, De Ridder M, Teunissen J, Kam B,

Keywords: gep-net, PRRT, treatment response, bone metastases,